- Moderna (MRNA) gains 13.79% on the day, reaching levels not seen since November 8 at $48.92.
- Vaccine manufacturers’ stocks rebound today after confirming the first death caused by H5N1 bird flu in the US.
Moderna (MRNA) shares rebounded from an intraday low of $42.86, where it attracted aggressive buyers who drove the share price to a three-month high of $48.92. At the time of writing, MRNA is trading at $48.24, up 13.27% on the day.
Vaccine companies rise on H5N1 bird flu fears
The United States announced the first deceased patient related to H5N1 bird flu yesterday. Following the news, shares of vaccine developing companies recorded significant gains today, led by Moderna (MRNA). This scenario could require increased government funding to cover vaccine orders once they are authorized by regulators. MRNA is currently trading at $48.04, gaining 13.27% on Tuesday and reaching a maximum not seen since November 8 at $48.92.
On the same page are the shares of Novavax (NVAX), which sign their fifth consecutive session on the rise, reaching their highs of October 16 at $11.55. So far, specialists consider this scenario to be a low risk for public health, since no evidence of human-to-human transmission has been identified.
Moderna technical levels
MRNA stock established short-term support given by the December 19, 2024 low at $37.45. The next key support is at $35.81, the November 15 pivot point. We observe the closest resistance zone at $56.67, maximum of November 7, 2024.
MRNA 4-hour chart
Source: Fx Street
I am Joshua Winder, a senior-level journalist and editor at World Stock Market. I specialize in covering news related to the stock market and economic trends. With more than 8 years of experience in this field, I have become an expert in financial reporting.
